Abstract
Neovessel formation is a pre-requisite for tumour growth and dissemination. Inhibition of angiogenesis is a promising approach for the treatment of neoplasms. In recent years, antiangiogenic drugs, such as TNP-470, have entered clinical trials. In this paper, we review the key experimental and clinical data on the role of TNP-470 in anti-tumour treatment.
Keywords: angiogenesis, applications, cancer, clinical testing
Full Text
The Full Text of this article is available as a PDF (156.1 KB).